ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Bevacizumab on Corneal Neovascularization (BQ-1-08-ARVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00797303
Recruitment Status : Completed
First Posted : November 25, 2008
Last Update Posted : December 2, 2011
Sponsor:
Information provided by (Responsible Party):
Joao Nassaralla, Instituto de Olhos de Goiania

Brief Summary:
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Condition or disease Intervention/treatment Phase
Corneal Neovascularization Drug: Bevacizumab Phase 4

Detailed Description:

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Bevacizumab on Corneal Neovascularization
Study Start Date : January 2006
Actual Primary Completion Date : July 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
Drug: Bevacizumab
subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months



Primary Outcome Measures :
  1. The Effect of Bevacizumab on Corneal Neovascularization [ Time Frame: Compare the results ]
    Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Corneal Neovascularization
  • Stable lesion

Exclusion Criteria:

  • Diabetes
  • Autoimmune diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00797303


Sponsors and Collaborators
Instituto de Olhos de Goiania
Investigators
Study Chair: Belquiz A Nassaralla, PhD Instituto de Olhos de Goiânia

Responsible Party: Joao Nassaralla, Clinical Professor, Instituto de Olhos de Goiania
ClinicalTrials.gov Identifier: NCT00797303     History of Changes
Other Study ID Numbers: BQ-1-08-ARVO
First Posted: November 25, 2008    Key Record Dates
Last Update Posted: December 2, 2011
Last Verified: November 2011

Keywords provided by Joao Nassaralla, Instituto de Olhos de Goiania:
bevacizumab
cornea
neovascularization

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents